Novo Nordisk says it has not yet posted details about new CagriSema trial
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
Novartis AG (NOVN) Gets a Hold from Jefferies
Jefferies analyst Peter Welford maintained a Hold rating on Novartis AG (NOVN – Research Report) today and set a price target of ...
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat Estimates
Teva Pharmaceutical Industries TEVA reported fourth-quarter 2024 adjusted earnings of 71 cents per share, which beat the ...
Medscape1m
Heavy Menstrual Bleeding: How Hematologists Can Help
Increased menstrual blood loss can be hard to measure and may detract from a woman’s quality of life, but a range of ...
Novo Nordisk Shares Still Have a Long Road Back from 40% Slump
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
Novo Nordisk A/S Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information – NVO
NEW YORK, NY / ACCESS Newswire / January 30, 2025 / If you suffered a loss on your Novo Nordisk A/S (NYSE:NVO) investment and want to learn about ...
BioPharma Dive10h
Metsera, Maze secure combined $415 million in IPOs
The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...
Insulin Pen And Pump Market Expansion Forecasted At 6.97% CAGR To 60.0 Billion USD By 2032 Abbott Laboratories, Roche
Key market drivers of the Insulin Pen and Pump market include the rising prevalence of diabetes, advancements in insulin delivery technologies ...
Bloomberg L.P.19h
Novo Nordisk A/S
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...